Aethlon Medical Inc.
Aethlon’s Hemopurifier used to treat Ebola patient in Germany
Pentagon awards $78m in contracts to 5 medtech companies
Aethlon seeks $2M for Hemopurifier blood filter
Aethlon Medical (OTC:AEMD) is looking to raise $2 million in an equity offering as it pursues a nod from the FDA for its Hemopurifier device.
Endo Health taps new CFO from Becton Dickinson | Personnel Moves
DARPA grants $23M contract to Battelle, NxStage and Aethlon for a sepsis treatment
Lantheus CFO resigns | Personnel Moves
Lantheus Medical Imaging Inc. finance chief Jeffrey Young resigned from his post, effective August 9. The CFO’s shoes will be filled by interim finance chief John Golubieski, formerly the CFO of Fougera Pharmaceuticals and finance VP at King Pharmaceuticals.
Aethlon wins FDA approval for Hemopurifier blood filter trial
Aethlon Medical (OTC:AEMD) said the FDA granted an investigational device exemption for a feasibility trial of its Hemopurifier device, designed to filter pathogens and cancer cells from human blood.
DePuy Synthes, Brainlab ink integration pact | Wall Street Beat
Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes Spine said it inked a deal with Brainlab to develop integrated surgical navigation and imaging devices.
J&J nabs its 1st Chinese device maker | Wall Street Beat
Health care giant Johnson & Johnson (NYSE:JNJ) made its 1st acquisition in China this week, picking up Guangzhou Bioseal Biotech for an undisclosed amount.
J&J has been doing business in China for more than 25 years, including last year’s launch of a medical device and diagnostics innovation center there.
Covidien names new vascular leader | Personnel Moves
Covidien (NYSE:COV) named Stacy Enxing Seng president of its $1.4 billion global vascular therapies business.
Enxing Seng, 47, will lead the division’s 4,000 employees, reporting to Peter Wehrly, president of the Mansfield, Mass.-based firm’s respiratory & monitoring solutions and vascular therapies division. She joined Covidien in July 2010 after the company spent $2.6 billion acquiring ev3 and its Pipeline embolization treatment for cerebral aneurysms.